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NeurotoxicityProton therapy offers an attractive alternative to conventional photon-based radiotherapy in low grade
glioma patients, delivering radiotherapy with equivalent efficacy to the tumour with less radiation expo-
sure to the brain. In the Netherlands, patients with favourable prognosis based on tumour and patient
characteristics can be offered proton therapy. Radiation-induced neurocognitive function decline is a
major concern in these long surviving patients. Although level 1 evidence of superior clinical outcome
with proton therapy is lacking, the Dutch National Health Care Institute concluded that there is scientific
evidence to assume that proton therapy can have clinical benefit by reducing radiation-induced brain
damage. Based on this decision, proton therapy is standard insured care for selected low grade glioma
patients. Patients with other intracranial tumours can also qualify for proton therapy, based on the same
criteria. In this paper, the evidence and considerations that led to this decision are summarised.
Additionally, the eligibility criteria for proton therapy and the steps taken to obtain high-quality data
on treatment outcome are discussed.
 2020 The Author(s). Published by Elsevier B.V. Radiotherapy and Oncology 154 (2021) 283–290 This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Radiotherapy is an important treatment modality in the man-
agement of low grade glioma (LGG). The optimal timing of radia-
tion treatment in the disease course is a dilemma in patients
with minimal symptoms and favourable prognosis [1]. Early treat-
ment can postpone tumour progression, a process that is otherwise
continuously on going. Deferring treatment can postpone side
effects, however, inevitably results in larger treatment volumes.
Tumour progression and radiotherapy both adversely affect neu-
rocognitive function (NCF). Whether tumour progression or
radiation-induced late effects are more detrimental in the long
term remains to be determined.
Proton therapy is an emerging radiotherapy modality that has
become available in several countries over the last years, includingin the Netherlands since 2018. The implementation of proton ther-
apy in clinical practise is more challenging than that of other tech-
nologies in radiotherapy. This is due to higher costs, limited
availability, and lack of level 1 evidence showing superior clinical
outcome [2]. In the Netherlands, the model-based approach is con-
sidered an alternative evidence-based methodology by health care
authorities, to select patients for proton therapy [3]. Model-based
selection entails, calculating the dose reductions that can be
obtained in normal tissues with proton therapy, compared to the
most optimal photon technique (plan comparison). Subsequently,
normal tissue complication probability (NTCP) models are used
to translate the dose differential into a toxicity risk reduction esti-
mation (DNTCP) [4,5]. When the expected clinical outcome in
terms of reduced toxicity is considered clinically relevant, a patient
is eligible for proton therapy.
For LGG patients, proton therapy is an attractive alternative to
conventional photon-based radiotherapy. Due to the physical prop-
erties of the proton beam, treatment can be delivered with signifi-
cantly less radiation exposure (dose and volume effect) to the
unaffected brain thus potentially limiting late radiation-induced
side effects including NCF decline [6–8]. Despite its relevance, NCF
is a difficult clinical endpoint to evaluate and quantify, and currently
Proton therapy for selected low grade glioma patients in the Netherlandshigh-quality NTCP-models for NCF outcome, necessary to give clin-
icalmeaning to the superiordosedistributionof protons, are lacking.
As a consequence, the model-based approach for selecting patients
with LGG for proton therapy is not yet achievable. There is, however,
multifaceted evidence on radiation-induced brain damage (RIBD)
from pre-clinical, radiological and clinical studies. An argument
wasmadeby theDutchRadiationOncologySociety to allowanalter-
native approach to select patients with LGG and other intracranial
tumours for proton therapy, and to define a new standard indication
for these patients in addition to other approved standard indications
such as paediatric patients and adult patients that require cran-
iospinal axis irradiation.
In July 2019, the National Health Care Institute in the Nether-
lands concluded that there is scientific evidence to assume that
proton therapy in LGG patients may have clinical benefit and
advised the Ministry of Health to accept proton therapy as stan-
dard insured care for selected LGG patients. In this paper, the evi-
dence and considerations that led to this decision are summarised.
The focus in this paper lies specifically on WHO grade II LGG
patients. However, patients with grade III anaplastic glioma’s and
other intracranial tumours can also qualify for proton therapy,
based on the same criteria. The eligibility criteria for proton ther-
apy and the steps taken to obtain high-quality data on treatment
outcome, necessary to enable model-based selection in the future,
are discussed.Low grade glioma
Prognosis and management
WHO grade II LGG is a brain tumour with moderate malignancy
grade that manifests as a slow progressive disease. The majority of
patients are young to middle aged adults, who are in a good clinical
condition at the time of diagnosis [9]. Classification is based on
histo-morphological and molecular features into oligoden-
droglioma and astrocytoma with or without mutated isocitrate
dehydrogenase (IDH) [10]. The relevance of the traditional catego-
rization of glioma into WHO grade II/low grade and WHO grade III/
anaplastic for prognostication has moved to the background. The
survival of oligodendroglioma and IDH mutated astrocytoma
patients often exceeds 10 years [11].
The standard of care for WHO grade II LGG is maximum safe
resection followed by radiotherapy and chemotherapy [12]. In
favourable cases, amore conservative approachwith careful clinical
and radiological follow up is an accepted alternative strategy, defer-
ring treatment and its side effects [1]. A potential downside of defer-
ring radiotherapy is that this strategy inevitably leads to larger
radiation treatment volumes and could therefore induce more side
effects. The so called ‘wait and scan strategy’ is the focal point of
the recently opened EORTC trial [clinicaltrials.gov identifier
NCT03763422]. Omitting radiotherapy as first line treatment after
surgery, using chemotherapyonly, is under investigation in anaplas-
tic oligodendroglioma [clinicaltrials.gov identifier NCT02444000].Radiotherapy
Even-though the traditional discrimination between WHO
grade II and III glioma has lost its importance in prognostication,
in current radiotherapy practise the tumour grade remains rele-
vant as this has consequences for the target volume definition as
well as dose prescription. The recently updated Dutch radiotherapy
consensus guidelines for WHO grade II LGG are identical for
proton- and photon-based techniques. The target volume includes
the visible tumour on MRI-FLAIR plus a 3D margin of 5 millimetres,
adapted to anatomical barriers. The prescribed dose is 50.4 GyRBE,
using conventional 1.8 GyRBE fractions, 5 times per week. Depend-284ing on location of the target volume, treatment plans are optimised
on circumstantial radiation dose to the pituitary, cochlea, scalp,
structures in the orbit, optic-chiasm and -nerves, brainstem and
brain including the hippocampi [13]. Using daily image guidance,
treatment is delivered robustly with 1–3 millimetre accuracy.
The physical properties of proton- and photon-based therapy are
essentially different [14].Where a photon beamcan bemanipulated
in a two-dimensional fashion (perpendicular to the beamdirection),
the proton beam has finite range and therefore can be controlled in
depth. As a result, photon and proton plans differ significantly in the
intermediate to lowdose range [6–8].Withproton therapy, dose to a
large volume of brain, including the contralateral hemisphere and
hippocampus, can be reduced to near-zero in most cases.
Although the effectiveness of photons and protons has not been
directly compared, the available data do not suggest inferior out-
come of protons on tumour control [15–17]. The circumstantial
low to intermediate dose (30 GyRBE) in a large volume of the
brain, typical of photon-based treatment plans, is not considered
to have a noteworthy contribution to tumour control in glioma
[18,19]. In brain tissue, proton therapy can have a higher biological
effect at the distal edge of the beam. Imaging changes after proton
therapy on MRI are more frequently seen than after photon ther-
apy [20,21]. Since the prescribed dose for WHO grade II LGG is well
under the tolerance dose of the brain, this is not a major concern in
these patients. However, extra care is warranted when treating in
eloquent regions such as the optic chiasm and brainstem, or to
higher dose near or beyond the tolerance dose of the brain (54
GyRBE) as in anaplastic glioma [22].Clinical outcome
The most common toxicities of radiotherapy for LGG patients in
the acute phase include fatigue, worsening of focal neurological
symptoms and hair loss, which usually resolve within a few
months [1,23,24]. In the long term, irreversible adverse effects
can develop. Endocrinopathies and decline in hearing function is
relevant in patients exposed to significant radiation dose to the
pituitary and/or cochlea [25]. NCF decline is considered to be a rel-
evant late adverse effect, irrespective of tumour location [26].
Impairments in the NCF adversely affect quality of life, patient’s
independent functioning within society (instrumental activities
of daily living (iADL)) and may have additional implications for
the patient’s proxies [27].
Most LGG patients will experience NCF decline over the course
of their disease [28,29]. The cause is multifactorial, including the
tumour itself, surgery, medical treatment (chemotherapy and
anti-epileptic drugs) and radiotherapy [30–32]. The magnitude of
contribution of the radiotherapy is currently not known [26]. Due
to the many competing risk factors for NCF decline in LGG patients,
radiation induced NCF decline is considered to be particularly rel-
evant in the long term [33,34]. Complaints and impairments are
systematically reported after photon radiotherapy, with worse out-
comes with increasing brain dose and volume parameters as well
as time intervals, indicating a chronic progressive clinical course
[28,29,35–38]. The first study on NCF outcome after proton therapy
had promising results, showing no NCF decline after 5 years [39].Radiation-induced brain damage
Pathophysiology
RIBD is a complex process that includes multiple pathophysio-
logical responses over time [40]. Within hours, radiation triggers
a cascade of molecular and cellular processes which may result
in cell loss within different cell lineages and brain regions [41].
Depending on the cells and regions involved, various pathophysio-
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cells may interfere with neurogenesis [42 43]. Loss of oligodendro-
cyte progenitors leads to white matter injury and demyelination
[44], and endothelial damage can result into (micro)vascular
changes and disruption of the blood–brain barrier [45]. Addition-
ally, radiation stress on mature neuronal cells alters dendritic mor-
phology and synaptic function [46]. Alongside all of these
processes, the brain can enter a potentially chronic neuro-
inflammatory state with activation of microglia and astrocytes
and infiltration of peripheral immune cells [47,48].Imaging
Imaging is an important tool to detect and quantify RIBD in a
patient over time. Radiation responses on molecular and cellular
levels can result in anatomical and functional changes that can
be visualised using MRI and PET based imaging [40,49]. Novel
high-resolution techniques enable a more intricate and early eval-
uation of microstructural changes [50].
Anatomical changes in the grey matter that have been observed
in the first year after radiotherapy include volume loss of the hip-
pocampus [51,52], atrophy of the amygdala [53], and thinning of
the cerebral cortex [54,55]. In the white matter, radiation-
induced changes become apparent as either volume loss or white
matter lesions that can be visualised on conventional MRI
[56,57]. However, diffusion tensor imaging is a more sensitive
MRI technique, which enables early detection of microstructural
changes in the white matter [58–61]. White matter lesions may
represent various pathophysiological processes including degener-
ation and cell loss, demyelination, astrogliosis and ischemic (mi-
cro)vasculopathy [62]. The grey matter and white matter display
regional differences in radiation sensitivity [63–65]. Other anatom-
ical changes that are seen after radiation include vasogenic brain
oedema resulting from an increased blood–brain barrier perme-
ability, and cerebral microbleeds due to structural damage to the
microvasculature [50].
Functional changes can already be observed after radiation in
the absence of any overt anatomic pathology. MRI spectroscopy
is a functional imaging tool to detect and characterise alterations
is metabolism. Neuronal damage can be signalled by changes in
the chemical constituents. Within months after radiation treat-
ment, signs of neuronal dysfunction can be observed [66,67]. Func-
tional MRI and perfusion MRI measure neuronal activity indirectly
through the measurement of changes in blood oxygenation and
blood flow. Decreased neuronal activity can be found up to several
months after radiotherapy in the higher dose regions [68,69].
Another interesting method to detect functional changes in the
brain is by the use of PET imaging. Several PET tracers are already
available for imaging of relevant processes involved in RIBD,
including tracers for activated glial cells, cerebral blood flow, neu-
ronal integrity, blood–brain barrier permeability, synaptic density,
myelin density and various neuro-receptors and transporters [70–
74]. So far, however, there is only limited data in the RIBD field
[75].Clinical course
The clinical presentation of RIBD is diverse, including both gen-
eral and more specific symptoms and impairments [76]. The clini-
cal course typically consists of an acute or early phase (during
treatment, lasting up to 12 weeks post treatment) and a late-
delayed phase (months to years after treatment). In the early phase
general symptoms, including fatigue and somnolence resulting
from brain oedema and transient demyelination, are the drivers
of the clinical picture. The late-delayed phase is characterised by
decline in NCF usually within multiple domains, showing a pro-285gressive worsening over time. Late radiation-induced NCF decline
is a result of structural and functional brain damage, and the
expressed clinical profile is dependent on the anatomical regions
involved [77].
Several factors inhibit the opportunity to perform high-quality
clinical studies necessary to increase our understanding of the clin-
ical impact of RIBD [78,79]. No neurocognitive test has been devel-
oped for frequent repetitive evaluations, available tests are not
adapted for use in neuro-oncological patients, and test batteries
require specialised experts and are time-consuming for patient
and caregiver. Finally, there is no systematic way to objectively
quantify and grade the severity of neurocognitive impairments.
NCF decline occurs systematically after partial and whole brain
radiation for primary and secondary brain tumours [26,33,80], as
well as patients with head and neck tumours [81]. Advanced radio-
therapy techniques with overall less radiation exposure to the
brain (dose and volume reduction) compared to more conventional
techniques improve neurocognitive outcome. This has been shown
for photon techniques in patients with brain metastases and low
grade brain tumours [80,82], as well as proton versus photon tech-
niques in paediatric brain tumour patients [83,84]. The hippocampi
are a relevant subvolume of the brain for NCF endpoints. Selective
sparing of radiation dose to the hippocampi in whole brain radia-
tion for brain metastases results in better preservation of memory
function [85,86]. And several other studies in low grade and paedi-
atric brain tumour patients report on dose–effect relationships in
the brain [87–89]. Even though these studies are conducted in a
variety of patient groups, and no high-quality NTCP model has
been developed yet, these studies confirm the proof of principle
that less radiation dose to the brain leads to better NCF outcome
in brain tumour patients.
Dutch eligibility criteria for proton therapy in LGG and other
intracranial tumours
We can conclude that radiation to the brain can induce damage
through the initiation of several pathophysiological processes. This
RIBD results in clinically meaningful NCF decline and is a major
concern in patients with favourable long-term prognosis that
require radiotherapy early in their disease course. Proton therapy
offers the opportunity to significantly reduce the radiation expo-
sure to the brain (dose and volume reduction) without compromis-
ing on efficacy. It is plausible that this reduction in radiation
exposure to the brain will lead to better clinical outcome of treat-
ment in terms of toxicity. The patients that are expected to benefit
most from proton therapy have a long prognosis and good clinical
performance before start of therapy.
In the Netherlands, the most favourable LGG patients with an
indication for radiotherapy are eligible for proton therapy. Eligibil-
ity criteria are: (1) good prognosis, defined as an expected 10-year
survival of 50% or higher; (2) good clinical and neurocognitive sta-
tus prior to radiotherapy, defined as a Karnofsky performance sta-
tus of 80 or higher and iADL independent function; (3) dose benefit
of proton therapy over photon therapy, defined as more than 5%
dose reduction to the supratentorial brain and/or both hippocampi
outside the target volume. This last criterion serves as a quality
check, to assure that no patients are treated with proton therapy
that would have better dosimetrics with (stereotactic) photon
therapy. Due to the typical size and lateralisation of the treatment
volumes in LGG patients, this parameter does not contribute much
to LGG patient selection and is more relevant for other intracranial
tumours with more central location and/or small target volume. An
illustrative LGG case is presented in Fig. 1.
Patients with anaplastic glioma, who fulfil all the above-
mentioned criteria, are eligible as well. However, the higher dose
prescribed for these tumours and consequential toxicities that
Fig. 1. Illustration of a typical LGG case selected for proton therapy in the Netherlands. (A) 38 year old woman, presentation with epilepsy only and a left frontal tumour on
FLAIR MRI (left). Using an advanced neurosurgical technique (awake craniotomy) maximum safe sub-total resection was performed, FLAIR MRI (right). Post-operatively the
patient remained in a good clinical condition (Karnofsky score 90) without any neurological deficits and good neurocognitive performance (iADL independent functioning).
Pathological examination of the tumour showed an oligodendroglioma WHO grade II, with complete co-deletion of 1p and 19q and IDH 1/2 mutation. The estimated 10 year
survival with adjuvant radiotherapy and chemotherapy is 80% [11]. This patient is at risk for radiation-induced NCF decline. (B and C) The dose distribution using a 2 field,
intensity modulated, proton technique (B), and a volumetric intensity modulated arc photon technique (C) is shown. Both plans are optimised on supratentorial brain (pink)
and hippocampi (yellow) dose, assuring adequate robust dose to the CTV (black). With the photon technique there is an inevitable low – intermediate dose bath to a large
volume of brain. With the proton technique a large volume of brain receives zero dose. (D and E) The dose difference in the supratentorial brain minus CTV (D) and both
hippocampi minus CTV (E) using protons instead of photons is 62% (8.27 Gy) and 96% (3.11 Gy) respectively. This dose reduction is accepted as being clinically relevant.
Proton therapy for selected low grade glioma patients in the Netherlandscould potentially be more substantial with proton therapy [21,22],
should be weighted as well. Other tumour entities in or around the
brain with similar or better prognosis than LGG, are also eligible for
proton therapy, provided that the dose to the brain with photon
treatment becomes relevant (i.e. small targets are preferably trea-
ted with stereotactic techniques).
Towards model-based selection
The development of NCF-based NTCP models in LGG patients is
a laborious but essential effort to move forward. Being able to pre-
dict the impact of radiotherapy can not only support patient selec-
tion for proton therapy (or other technological radiotherapy
innovations) but will also help decision making during treatment
planning and may even give some direction on choosing the opti-
mal timing of radiotherapy.286Implementation of structural evaluation of NCF in routine
clinical practise is challenging. Subjective evaluations using
PROMs are not correlated to objective evaluations [90]. Short
screening tools such as the Minimal Mental State Examination
(MMSE) or Montreal Cognitive Assessment (MoCA) have a low
sensitivity for detection of NCF impairments in LGG [91]. There-
fore a battery of neuropsychological tests, covering multiple NCF
domains, is recommended to evaluate NCF [78,92]. Since there is
a potential bias when re-testing a patient, the timing of these
evaluations should be planned strategically and not too fre-
quent. At this moment the applicability of the CTCAE [93] is
limited for grading any NCF-based endpoint. Evaluation of iADL
along with NCF might prove to be useful, to grade the severity
of NCF impairments and give more clinical meaning to these
endpoints.
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torial brain, infratentorial brain or cerebellum, brainstem and
specific subvolumes of the brain such as the hippocampi [13,89].
Other volumes that might be of interest include brain areas that
can be assigned to a specific NCF-based endpoint, as well as speci-
fic white matter tracts or brain nuclei and cortex [94]. However,
the brain is the most intricate, complex organ of the human body:
the brain does not contain independent functional units [95]; func-
tional brain areas can change over time (plasticity) [96]; and the
communication within the brain through neuronal networks is a
phenomenon that we are only just beginning to understand [97].
LGG is a relatively rare disease, and collaboration within the
radiation oncology society is necessary to obtain large datasets
needed for model development and validation. In the Netherlands
we expect to treat at least 100 LGG patients per year with proton
therapy, for whom all relevant patient, tumour and treatment
characteristics are registered. Prospective evaluation of NCF with
a standardised neuropsychological test battery (including the Hop-
kins Verbal Learning Test, Trail Making Test part A&B and Con-
trolled Oral Word Association test), as well as fatigue and iADL
evaluations are mandatory for patients receiving proton therapy
and strongly advised for patients receiving photon therapy or wait
and scan approach. Patients are evaluated at start of treatment and
every 2.5 years there-after. A large variability in dosimetrics of
brain and substructures of the brain is expected since the selection
criterion for dose advantage with protons has a low threshold of
5%, which is easily met for LGG patients. This variability will facil-
itate the assessment of dose effect relationships in the brain and
substructures of the brain. The first analysis of the collected data
is planned after the first 100 patients have had their 5 year
follow-up evaluations [clinicaltrials.gov identifier expected soon].
A national electronic infrastructure to share and manage the data
is being created. Where-as these mandatory clinical evaluations
are already implemented in the Netherlands, similar efforts are
currently ongoing within the European Particle Therapy Network
as well.
Discussion
This paper specifically describes the Dutch approach for select-
ing LGG patients for proton therapy. Since the financial, political
and health care landscape is unique to every country, the purpose
of this paper is not to dictate but merely to inform practitioners
about the Dutch policy. At present, there are three Proton Therapy
Centre’s (PTCs) in the Netherlands, all are affiliated to large aca-
demic radiation oncology departments. The geographic distribu-
tion is in such a way, that proton therapy is easily accessible to
almost all patients without the need for on-site accommodation.
The extra treatment delivery costs of proton therapy are financed
through an obligatory social medical insurance system.
In patients with favourable LGG and expected long survival,
radiation-induced NCF decline is of major concern. Since the main
goal in treating these patients is not only to optimise survival but
also to minimise toxicity and preserve quality of life, several radi-
ation technique innovations have been implemented over the
years with the aim of reducing dose to the brain and specifically
the hippocampi as a relevant substructure of the brain for NCF end-
points. Innovations that are now considered standard of care
include: more complex and conformal techniques (intensity mod-
ulated and stereotactic techniques), image guided delivery of treat-
ment, and MRI guided target definition. Proton therapy is the next
step in this technical evolution of radiotherapy, combining high
conformity of prescribed dose to the target with avoidance of cir-
cumstantial intermediate to low dose to large volumes of brain.
Most technical innovations in radiotherapy are implemented with-287out results from RCTs based on the As Low As Reasonably Achiev-
able (ALARA)-principle. However, considering the magnitude of
costs involved and the influence on patients and caregivers, it
makes sense that for proton therapy different requirements for
clinical implementation apply.
Obtaining level 1 evidence in LGG is challenging, due to the low
incidence and long-term overall survival of patients that may
exceed 10–15 years after completion of treatment. Studies typi-
cally have long running times and by the time results are pub-
lished, there is a likelihood of significant policy changes that may
hamper the interpretation of the data. In addition, radiotherapy
specific conclusions from clinical studies are impeded because
technical developments move into clinical practise rapidly. The
techniques used in clinical studies will therefore be regarded as
out-dated at the time definitive results become available. Whether
we will be able to obtain level 1 evidence on proton therapy
through a RCT in LGG is questionable. In the Netherlands, it was
concluded that a RCT photons versus protons in LGG was not feasi-
ble for several reasons: (1) the primary endpoint should be NCF,
since differences in NCF after radiotherapy are not expected to be
significant within the first years after treatment, a long follow-up
time is necessary; (2) low patient numbers and several significant
confounding factors will imply a long accrual time; (3) a large bud-
get is needed, since the finances for proton therapy (being the
experimental arm) will not be covered by medical insurance; and
(4) concerns about the caregivers and patients motivation to con-
tribute or participate: whether there is true clinical equipoise can
be debated. However, at least one randomised phase II trial is cur-
rently open in the United States [clinicaltrials.gov identifier
NCT03180502], and another randomised trial is being initiated in
the United Kingdom [98]. The progress and results of these studies
are followed with great interest.
Model-based selection is an alternative scientific approach for
implementation of proton therapy, accepted in the Netherlands
by health care authorities [4,5]. Unfortunately, the model-based
approach is not achievable in LGG patients, since the essential data
to quantify the effect of dose reduction on the brain or relevant
brain substructures such as the hippocampi is either lacking or of
poor quality. Also the often quoted hippocampus model by Gondi
[89] did not pass the minimal quality requirements for model-
based selection [5]. Within the Netherlands Society for Radiation
Oncology, there was a preference for introducing proton therapy
as a standard radiation option for selected LGG patients: an empir-
ical approach. This does not imply that every eligible LGG patient
should be treated with proton therapy. The national indication pro-
tocol for proton therapy is merely a tool for a careful clinical imple-
mentation of proton therapy and making proton therapy an
insured treatment option for eligible patients. However, there will
be patients that prefer to be treated closer to home, without refer-
ral to a PTC. Whether or not the patient is referred for proton ther-
apy is a typical example of shared decision making between the
radiation oncologist and patient in the local treatment centre.
Finally, the clinical introduction of proton therapy for LGG
patients in the Netherlands should be considered an academic
approach. The current data on radiation induced NCF impairments
in LGG patients consists of low-certainty evidence and the magni-
tude of the radiotherapy impact is uncertain. It is a challenge to
investigate, in this young research niche, the true value of proton
therapy. However, each PTC is affiliated to at least one large aca-
demic radiation oncology department and it is mandatory to
prospectively evaluate NCF by a standard neuropsychological test
battery in every patient that receives proton therapy. This central-
ization and intensification of care will be the foundation for many
research projects, both local and (inter)national. The focus will be
on developing NTCP models for NCF outcome after radiotherapy,
Proton therapy for selected low grade glioma patients in the Netherlandsto enable model-based selection for proton therapy in LGG patients
in the future.
In conclusion, well-selected patients with LGG and other
intracranial tumours have favourable prognosis, with overall sur-
vival rates extending beyond 10 years. A significant subset of
patients is treated with radiotherapy early in the disease course,
and late radiation-induced NCF effects are of major concern. There
is convincing evidence that radiation to the brain impairs NCF. It is
plausible that reducing radiation dose to the brain by using proton
therapy is clinically relevant in selected patients. Since there are
multiple factors in LGG patients affecting NCF outcome, radiation
effects are not expected to become detectable and clinically rele-
vant within the first years after treatment.
Proton therapy is an approved radiotherapy option for selected
LGG patients by health care authorities in the Netherlands. In the
coming years collaborative efforts will be made within the Nether-
lands Society of Radiation Oncology to prospectively evaluate and
register NCF outcome data with the intention to develop NCF-
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